Skip to main content
. 2015 Sep 4;2015(9):CD009061. doi: 10.1002/14651858.CD009061.pub2

Comparison 1. A. Anti‐pseudomonas penicillins: piperacillin‐tazobactam vs ticarcillin‐clavulanate.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Clinical resolution of the infection 1 63 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [0.59, 2.29]